Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

530 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.
Buurman ET, Timofeyeva Y, Gu J, Kim JH, Kodali S, Liu Y, Mininni T, Moghazeh S, Pavliakova D, Singer C, Singh S, Handke LD, Lotvin J, Prasad AK, Scully IL, Donald RGK, Jansen KU, Anderson AS. Buurman ET, et al. Among authors: anderson as. J Infect Dis. 2019 Jun 5;220(1):105-115. doi: 10.1093/infdis/jiz062. J Infect Dis. 2019. PMID: 30778554 Free PMC article.
Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design.
Nanra JS, Timofeyeva Y, Buitrago SM, Sellman BR, Dilts DA, Fink P, Nunez L, Hagen M, Matsuka YV, Mininni T, Zhu D, Pavliak V, Green BA, Jansen KU, Anderson AS. Nanra JS, et al. Among authors: anderson as. Vaccine. 2009 May 26;27(25-26):3276-80. doi: 10.1016/j.vaccine.2009.01.062. Epub 2009 Feb 5. Vaccine. 2009. PMID: 19200819
Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.
McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris SL, Scott AA, Tan C, Mack M, DaSilva I, Alexander K, Mason K, Jiang HQ, Zhu D, Mininni TL, Zlotnick GW, Hoiseth SK, Jones TR, Pride MW, Jansen KU, Anderson AS. McNeil LK, et al. Among authors: anderson as. Vaccine. 2009 May 26;27(25-26):3417-21. doi: 10.1016/j.vaccine.2009.01.075. Epub 2009 Feb 5. Vaccine. 2009. PMID: 19200847
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis.
Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, Deghmane AE, Kriz P, Musilek M, Kalmusova J, Caugant DA, Alvestad T, Mayer LW, Sacchi CT, Wang X, Martin D, von Gottberg A, du Plessis M, Klugman KP, Anderson AS, Jansen KU, Zlotnick GW, Hoiseth SK. Murphy E, et al. Among authors: anderson as. J Infect Dis. 2009 Aug 1;200(3):379-89. doi: 10.1086/600141. J Infect Dis. 2009. PMID: 19534597
Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.
Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, DaSilva I, Mack M, Zhao XJ, Pride MW, Andrew L, Murphy E, Hagen M, French R, Arora A, Jones TR, Jansen KU, Zlotnick GW, Anderson AS. Jiang HQ, et al. Among authors: anderson as. Vaccine. 2010 Aug 23;28(37):6086-93. doi: 10.1016/j.vaccine.2010.06.083. Epub 2010 Jul 7. Vaccine. 2010. PMID: 20619376
New frontiers in meningococcal vaccines.
Anderson AS, Jansen KU, Eiden J. Anderson AS, et al. Expert Rev Vaccines. 2011 May;10(5):617-34. doi: 10.1586/erv.11.50. Expert Rev Vaccines. 2011. PMID: 21604983 Review.
Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis.
Anderson AS, Scully IL, Timofeyeva Y, Murphy E, McNeil LK, Mininni T, Nuñez L, Carriere M, Singer C, Dilts DA, Jansen KU. Anderson AS, et al. J Infect Dis. 2012 Jun;205(11):1688-96. doi: 10.1093/infdis/jis272. Epub 2012 Apr 2. J Infect Dis. 2012. PMID: 22474033 Free PMC article.
Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.
Marshall HS, Richmond PC, Nissen MD, Jiang Q, Anderson AS, Jansen KU, Reynolds G, Ziegler JB, Harris SL, Jones TR, Perez JL. Marshall HS, et al. Among authors: anderson as. Pediatr Infect Dis J. 2012 Oct;31(10):1061-8. doi: 10.1097/INF.0b013e31826327e4. Pediatr Infect Dis J. 2012. PMID: 22718089 Clinical Trial.
530 results